FRANKFURT, April 15 (Reuters) - German biotech firm CureVac
said it had seen the number of requests for its
experimental COVID-19 vaccine increase over the past few days,
following a halt of the use of Johnson & Johnson's shot
amid concerns over rare side effects.
The European Union in November secured up to 405 million
doses of CureVac's two-shot vaccine, which has yet to win
regulatory approval, the company's only large supply contract so
far.
A spokesman said requests have been coming in from various
actors, including governments and international organisations
but he declined to elaborate. The group is to hold an analyst
call on fourth-quarter results at 1400 GMT.
Europe's choppy vaccine rollout hit more trouble this week
after J&J suspended shipments of its COVID-19 shot and Denmark
said it would drop a similar vaccine from AstraZeneca
over very rare cases of blood clotting.
(Reporting by Ludwig Burger, editing by Emma Thomasson)
Glaxosmithkline (GSK)
Astrazeneca (AZN)